mRNA Therapeutics Market Size And Forecast 2026–2030: Trends Driving Industry Expansion
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
mRNA Therapeutics Market Size And Revenue Outlook Through 2030
The mrna therapeutics market has experienced consistent expansion in recent years. This market is projected to expand from $35.9 billion in 2025 to $37.18 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 3.6%. Historically, this growth can be attributed to the breakthrough success of mrna vaccines in infectious diseases, advancements in nucleic acid delivery technologies, an increased understanding of gene expression control, early research validation of mrna-based protein synthesis, and strong public funding for mrna research platforms.
The mrna therapeutics market is anticipated to experience consistent growth in the coming years. It is projected to expand to $42.32 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 3.3%. This expansion during the forecast period can be attributed to several factors, including an escalating demand for targeted and personalized treatments, the broadening application of mrna in oncology and rare diseases, increased biopharmaceutical investment in mrna development pipelines, a growing number of mrna drugs entering clinical trials, and strategic alliances formed between biotech companies and research organizations. Significant trends expected during this period involve the diversification of mrna therapeutics beyond vaccines, an increasing focus on protein replacement therapies utilizing mrna, a burgeoning clinical pipeline for non-vaccine mrna drugs, heightened investment in lipid nanoparticle delivery systems, and the accelerated development of comprehensive mrna manufacturing capabilities.
Get A Free Sample Report With In-Depth Market Insights:
mRNA Therapeutics Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The future expansion of the mRNA therapeutics market is anticipated to be fueled by the rising occurrence of chronic and infectious ailments. These are health conditions, such as tuberculosis, HIV/AIDS, and hepatitis, that endure for significant durations and possess the ability to transmit from one person to another. Their increase is attributable to elements like enhanced global travel and shortcomings in medical infrastructure, leading to higher rates of spread and challenges in managing illnesses effectively. mRNA-based therapies aid in better disease management by swiftly prompting the body to generate immune-boosting proteins, thereby accelerating the creation of specific vaccines and medical interventions. As an illustration, data from March 2024 by the US government’s Centers for Disease Control and Prevention indicated a surge in tuberculosis cases, escalating from 8,320 in 2022 to 9,615 in 2023, which signifies a rise of 1,295 cases. Consequently, the expanding occurrence of chronic and infectious diseases is a key factor propelling the development of the mRNA therapeutics market.
mRNA Therapeutics Market Segment Analysis: What Are The Core Market Categories?
The mrna therapeutics market covered in this report is segmented –
1) By Product: Vaccines, Drugs
2) By Application: Infectious Diseases, Oncology, Rare Genetic Diseases, Respiratory Diseases, Other Applications
3) By End Use: Hospitals And Clinics, Research Organizations, Other End Uses
Subsegments:
1) By Vaccines: Infectious Disease Vaccines, Cancer Vaccines, Other Therapeutic Vaccines
2) By Drugs: Oncology Drugs, Cardiovascular Drugs, Autoimmune Disease Drugs, Other mRNA-Based Drugs
mRNA Therapeutics Market Innovation Trends Shaping Future Development
Leading firms within the mRNA therapeutics market are concentrating on creating novel approaches, like individualized neoantigen vaccines, to boost immune responses and better survival rates for cancer patients. These personalized neoantigen vaccines represent cancer treatments tailored for individual patients, leveraging distinct tumor-specific mutations to activate the immune system to identify and eliminate cancer cells. As an example, in July 2023, Merck & Co., Inc., a US-based biopharmaceutical company focused on research, collaborated with Moderna Therapeutics, Inc., a US-based biotechnology firm, to commence a Phase 3 randomized clinical study (V940-001). This trial aims to assess mRNA-4157 (V940) alongside KEYTRUDA® (pembrolizumab) as an adjuvant therapy for individuals suffering from resected high-risk (Stage IIB-IV) melanoma. This particular investigation is building upon favorable outcomes observed in the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial, where the combination demonstrated a significant advantage compared to KEYTRUDA by itself in lowering the risk of recurrence and distant metastasis. The ongoing Phase 3 trial is designed to validate these initial findings, with its primary and secondary endpoints being the evaluation of relapse-free survival and distant metastasis-free survival, respectively.
mRNA Therapeutics Market Top Companies Driving Competitive Growth
Major companies operating in the mrna therapeutics market are Pfizer Inc., Novartis AG, Sanofi AG, AstraZeneca plc, GlaxoSmithKline plc, Hoffmann-La Roche AG, Moderna Therapeutics Inc, BioNTech SE, Vertex Pharmaceuticals Incorporated, Catalent Inc, Alnylam Pharmaceuticals Inc, Sarepta Therapeutics Inc, Arcturus Therapeutics Holdings Inc, CureVac N.V, Ethris GMBH, eTheRNA immunotherapies NV, In-Cell-Art S.A.S., Nutcracker Therapeutics Inc, SCM LifeScience Co Ltd, Suzhou Abogen Biosciences Co Ltd, Tiba Biotech LLC, CSPC Pharmaceutical Group, CRISPR Therapeutics AG
View The Full mRNA Therapeutics Market Report:
mRNA Therapeutics Market Regional Analysis And Top Geography
North America was the largest region in the mRNA therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mrna therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
